Avidity Q2 2025: $1.2B cash, $620M Lonza deal, BLA submissions on track

Avidity Biosciences, Inc.

2025-Q2 EPS reported -$2.11 revenue$5,420,000

Entered $620M manufacturing services agreement with Lonza for commercial drug substance and product, 7-year term.
Collaboration revenue $3.8M in Q2 2025 (up from $2.0M) from BMS partnership.
R&D expenses $138.1M in Q2 (up from $63.9M); G&A expenses $36.9M (up from $20.7M).
Cash, equivalents and marketable securities ~$1.2B as of June 30, 2025; plus $185.5M net from ATM offering; cash runway to mid-2027.
Pipeline: del-zota BLA submission year-end 2025; del-brax H2 2026; del-desiran topline data Q2 2026.

item 1.01item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.